Literature DB >> 15013926

Anti-inflammatory pharmacotherapy during pregnancy.

Monika E Østensen1, Johan F Skomsvoll.   

Abstract

NSAIDs or cyclooxygenase inhibitors (COX inhibitors), including aspirin, are widely used to treat pain, fever and the articular symptoms of chronic rheumatic diseases. Manifestations of connective tissue or autoimmune diseases are commonly treated with glucocorticosteroids. The effect and side effects of NSAIDs depend on the isoforms of cyclooxygenases that they preferentially or selectively inhibit. The use of COX inhibitors has recently been associated with infertility and miscarriage. The classical nonselective COX inhibitors, including aspirin, do not increase the risk of congenital malformations in humans but administered in the latter part of gestation, they can affect pregnancy and the fetus. The ability of nonselective and selective COX inhibitors to prolong gestation has been used by obstetricians to inhibit premature delivery. The vascular effects of prostaglandin inhibitors can cause constriction of the fetal ductus arteriosus and reduce renal blood flow. These complications have been described for most nonselective COX inhibitors but are increasingly reported also for the selective COX-2 inhibitors. Aspirin, which causes irreversible inhibition of cyclooxygenases, differs from other NSAIDs with regard to indication, effects and side effects. Prematurity, which is increased in pregnancies of women with connective tissue diseases, is an additional risk factor for adverse effects of antenatal exposure to NSAIDs. Therefore, treatment with COX inhibitors should be discontinued at week 32 of gestation. The ability of NSAIDs to compromise reproductive function by inhibition of ovulation and as causative agents for miscarriage is still under debate. Glucocorticosteroids given in early pregnancy are a risk factor for the development of oral clefts. Therefore, the daily dose should be kept to <or= 15 mg during the first trimester. High doses of glucocorticosteroids in the second and third trimester are reserved for flares of autoimmune diseases. Intrauterine fetal growth restriction and premature delivery are possible side effects of high doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013926     DOI: 10.1517/14656566.5.3.571

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  14 in total

1.  [Medication therapy during pregnancy].

Authors:  S Gronau; A Neumann
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

2.  Prenatal constriction of the ductus arteriosus following maternal diclofenac medication in the third trimester.

Authors:  Karoline Aker; Anne Brantberg; Siri Ann Nyrnes
Journal:  BMJ Case Rep       Date:  2015-10-01

3.  Antenatal and Neonatal Antecedents of Executive Dysfunctions in Extremely Preterm Children.

Authors:  Alan Leviton; Robert M Joseph; Elizabeth N Allred; T Michael O'Shea; H Gerry Taylor; Karl K C Kuban
Journal:  J Child Neurol       Date:  2018-01-11       Impact factor: 1.987

Review 4.  Family Planning and Rheumatoid Arthritis.

Authors:  Nicole Hunt; Mehret Birru Talabi
Journal:  Curr Rheumatol Rep       Date:  2019-03-06       Impact factor: 4.592

Review 5.  Pharmacological treatment of migraine during pregnancy and breastfeeding.

Authors:  Siri Amundsen; Hedvig Nordeng; Kateřina Nezvalová-Henriksen; Lars Jacob Stovner; Olav Spigset
Journal:  Nat Rev Neurol       Date:  2015-04       Impact factor: 42.937

Review 6.  Pharmacological Management of Acute Endodontic Pain.

Authors:  Asma A Khan; Anibal Diogenes
Journal:  Drugs       Date:  2021-10-07       Impact factor: 9.546

7.  Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study.

Authors:  K Nezvalová-Henriksen; O Spigset; H Nordeng
Journal:  BJOG       Date:  2013-03-14       Impact factor: 6.531

Review 8.  Treating common ear problems in pregnancy: what is safe?

Authors:  Petros V Vlastarakos; Thomas P Nikolopoulos; Leonidas Manolopoulos; Eleftherios Ferekidis; George Kreatsas
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-11-23       Impact factor: 2.503

Review 9.  Treating common problems of the nose and throat in pregnancy: what is safe?

Authors:  Petros V Vlastarakos; Leonidas Manolopoulos; Eleftherios Ferekidis; Aris Antsaklis; Thomas P Nikolopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-12       Impact factor: 2.503

Review 10.  Pregnancy-related pelvic girdle pain: an update.

Authors:  Nikolaos K Kanakaris; Craig S Roberts; Peter V Giannoudis
Journal:  BMC Med       Date:  2011-02-15       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.